Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Driven Blood Test to Revolutionize Diagnosis of Long COVID in Children

By LabMedica International staff writers
Posted on 29 Jan 2025

Long COVID affects about 0. More...

5% of pediatric patients exposed to SARS-CoV-2. Also known as post-COVID or post-acute sequelae of SARS-CoV-2, this condition is characterized by persistent symptoms that appear after the viral infection and last for at least 8-12 weeks, significantly impacting daily life. Long COVID has been observed across all age groups, with children over the age of 10 being particularly affected in terms of severity. While proteomic studies have highlighted a pro-inflammatory signature and thrombo-inflammation in adults with long COVID, similar findings had not been documented in the pediatric population. Now, a new method can accurately diagnose long COVID in children using a blood sample and artificial intelligence (AI).

In a study led by researchers at Università Cattolica del Sacro Cuore (UCSC, Milan, Italy) and associated institutions, an AI tool was found to effectively detect the molecular signature of long COVID in plasma samples from pediatric patients, with an accuracy rate of 93%. For their research, the team performed a detailed protein analysis on blood plasma from children under 19 years of age, comparing those with long COVID to control groups including children with acute COVID-19, MIS-C, and healthy controls. Children were classified as having long COVID if they experienced persistent symptoms for at least 8 weeks after the initial infection, which negatively impacted their daily activities and could not be attributed to other causes. The study included 112 children, with 34 meeting the clinical criteria for long COVID, 32 with acute SARS-CoV-2 infection, 27 with MIS-C, and 19 healthy controls.

The study, published in the journal Pediatric Research, showed that children with long COVID showed higher expression of a specific set of pro-inflammatory and pro-angiogenic chemokines (CXCL11, CXCL1, CXCL5, CXCL6, CXCL8, TNFSF11, OSM, STAMBP1a) compared to controls. Using a machine learning model based on this proteomic profile, researchers identified long COVID with an accuracy of 93%, a specificity of 86%, and a sensitivity of 97%. The findings indicate that pediatric long COVID is characterized by an increased blood protein signature associated with ongoing general and endothelial inflammation, similar to what has been observed in adults. This study is the first to document the pro-inflammatory profile in children with long COVID, and the results may contribute to the development of future diagnostic tests.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Manual Pipetting Aid
Pipette Controllers macro
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.